Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Tagitanlimab in ESCC and G/GEJA
NCT07701681Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07701681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701681.